Immix Biopharma, Inc.
IMMX•NASDAQ•Healthcare•Biotechnology

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOIlya Rachman
Founded2014
IPO DateDecember 16, 2021
Employees21
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.immixbio.com
Phone310 651 8041
Address
11400 West Olympic Boulevard, Suite 200 Los Angeles, California 90064 United States

Corporate Identifiers

CIK0001873835
CUSIP45258H106
ISINUS45258H1068
EIN45-4869378
SIC2834

Leadership Team & Key Executives

Dr. Ilya Rachman M.B.A., M.D., Ph.D.
Co-Founder, Chief Executive Officer and Chairman
Gabriel Morris B.A.
Chief Financial Officer and Director
Dr. Graham Ross FFPM, M.D.
Chief Medical Officer and Head of Clinical Development
Sean Senn J.D., M.B.A., M.Sc.
Co-Founder
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.
Scientific Co-Founder
Dr. David Marks MBBS, Ph.D.
Chief Medical Officer of Cell Therapy
Mel Davis-Pickett
Head of CMC Technical Development
Michael A. Grabow
Chief Commercial Officer